Kynexis Launched to Advance Precision Therapeutics for Brain Diseases
Lead Candidate KYN-5356, a First-In-Class Small Molecule KAT-II Inhibitor, Advancing Toward the Clinic for Cognitive Impairment Associated With Schizophrenia…
Source: biztoc.com